Our Progress

November

Dr. Gary Wörtz has the idea for the Omega lens on a flight back from an ophthalmology conference.

February

Dr. Wörtz files a full utility patent for his idea.

January

Dr. Wörtz partners with Rick Ifland to legally form Omega Ophthalmics ® as a Limited Liability Company registered in Kentucky.

February

Omega files a PCT Patent for the Omega lens to protect its intellectual property in over 100 countries.

April

The first prototype of the Omega lens is designed by Rich Crist and manufactured by Specialty Silicone Fabricators.

September

Drs. Steven Slade, Richard Lindstrom and Eric Donnenfeld are the first additions to Omega's Medical Advisory Board.

Omega responds to first USPTO Office Action with amended claims.

Q4

Omega raises an angel round of funding to pursue prototype devices and animal trials.

January

Drs. John Berdahl and George O. Waring, IV join Omega's Medical Advisory Board.

February

Dr. William Trattler joins Omega's Medical Advisory Board.

June

Omega begins pursuit of multiple families of patents.

July

Drs. Werner and Mamalis of the University of Utah perform an animal study using lab rabbits to evaluate the surgical technique for implantation and method of insertion of the Omega Duetto implant.

Ifland and Wörtz meet with Steve Jensen of Knobbe Martens Olson & Bear LLP. Team develops strategic plan to expand its intellectual property to include numerous patents for each patent family.

Drs. Ike Ahmed, William Wiley, and Daniel Chang join Omega's Medical Advisory Board.

Omega holds two VIP preview luncheons to explain Omega's technology to leaders in the ophthalmic community.

August

Design revisions are made and a new prototype manufacted.

November

A Continuation of Omega's Alpha family of Patents is filed with USPTO for size, shape, function, and form of device.

December

Intellectual property portfolio grows into three patent “families” and IP further protected. Omega's core patent for a "prosthetic capsular bag and method of inserting the same" is issued by the USPTO.

Omega's Alpha family of patents is published in Europe.

January

Drs. Werner & Mamalis of the University of Utah perform a one-day animal study to evaluate the surgical technique for implantation and method of insertion of the revised Omega device.

February

Jonathan Soiseth hired on as Design Consultant for new device prototypes.

Animal study receives successful results.

March

4-week animal trial begins under supervision of Drs. Werner & Mamalis of the University of Utah.

Dr. Lilliana Werner delivers animal study results and pictures showing that the Gemini Refractive Capsule looks significantly better than the world's leading IOL after 4 weeks in a rabbit eye.

April

Omega CMO Dr. Gary Wörtz is named to the '40 Under 40' List by The Ophthalmologist.

A new prototype design with interchangable polyamide haptics is produced.

A Continuation of Omega's Bravo family of patents is filed with USPTO, including the discussion of the most recent animal trial results. 

May

Omega successfully completes its Series A round of funding, and final animal trial results are sent to Knobbe Martens to be included in patent families.

The first continuation of Omega's Alpha family of patents is published with the USPTO.

The second continuation of Omega's Alpha family of patents is published with the USPTO.

A Continuation of Omega's Charlie family of patents is published with the USPTO. 

June

Omega's patent for a "prosthetic capsular bag and method of inserting the same" is granted by the Canadian Intellectual Property Office.

Omega's patent for a "prosthetic capsular bag and method of inserting the same" is granted by the Japanese Patent Office.

Omega's Bravo family of patents is filed with both the USPTO and in the Patent Cooperation Treaty (PCT).

July

Jill Emerton is hired as a consultant CRO for Omega's offshore human trial. 

Omega's Alpha family of patents is issued in Japan.

Omega's Alpha family divisional patent allowance is granted in Japan.

August

Protocol design for Omega's offshore human trial begins.

Warren Hill, MD is added to Omega's Medical Advisory Board, calling the Omega device "a platform for innovation inside the eye."

Version 8 of the Omega prototype has 30-Diopter lens and fits through a 2.2 mm injector without problems, indicating that the entire design will fit through a 2.2 mm injector.

Omega's Alpha Family of Patents is issued in Australia.

A Notice of Allowance for a Continuation of Omega's Charlie family of Patents is issued by the USPTO.

September

Kevin Waltz, MD, an Indianapolis-based ophthalmologist is hired as a consultant for Omega human trials.  For decades, Dr. Waltz has led several trials in Central and South America.

October

Animal trials with the latest Omega prototype begin at the University of Utah under the direction of Drs. Lilliana Werner and Nick Mamalis.

ISR Written Opinion finds all claims in Omega's Bravo family of patents to be "novel and have industrial applicability."

November

Preliminary results from the animal trial validate the need for human trials to begin.

December

Lilliana Werner publishes successful results of October 2015 animal study.

Omega hires Lenstec Barbados for finished manufacturing, cleaning, and de-flashing of new prototype.

San Salvador, El Salvador is selected as the site for first-in-man human trial.

Omega's Charlie family of patents is filed with USPTO, which secures intellectual property for high technology devices inside the eye.

Omega's Charlie family of patents are filed in the Patent Cooperation Treaty (PCT).

Omega's Bravo family of patents and a first continuation of the Bravo family are published.

A Bravo family PCT application is published.

April

The Omega device is officially named the Omega Gemini Refractive Capsule. A trademark is filed with the USPTO.

Human trial protocols and finalized and submitted for approval.

A first Continuation of the Charlie family of patents is filed with the USPTO.

Charlie PCT International Search Report (ISR) and Written Opinion (WO) indicates that all claims "have novelty, inventive steps, and industrial applicability."

May

Omega begins discussions with several pharmaceutical and medical device companies about creating an “Omega Platform,” as the Omega device may be an ideal receptacle for their novel drug treatments inside the eye.

Omega's Charlie family of patents is filed with the USPTO.

June

Omega's Charlie family of patents is issued by the USPTO.

Omega's first Provisional Delta family of Patents are filed with the USPTO.

July

Omega receives a Notice of Allowance for its Bravo family of patents. 

August

Omega receives a Notice of Allowance for its 2nd continuation of the Alpha family of patents.

A 2nd Continuation of the Bravo family of patents is filed with USPTO; a 1st Continuation of the Bravo family of patents issued by USPTO.

The Charlie PCT patent and the 1st Continuation of the Charlie family of patents are published.

September

Omega receives Notice of Acceptance of Statement of use from the USPTO to use the name OMEGA OPHTHALMICS on or in connection with “Ophthalmic-based goods, specifically, implantable lenses.”

A 2nd Continuation of the Alpha family of patents is issued by USPTO.

A Notice of Allowance for the 1st Continuation of the Charlie family of patents received from USPTO.

A 5th Divisional Patent of the Charlie family is allowed by USPTO, which contains claims surrounding attachable optics.

November

A 4th Divisional Patent of the Charlie family is allowed by USPTO.

Omega's first Provisional Echo family of Patents are filed with the USPTO.

Omega receives a notice of allowance for its Alpha family of patents in Europe, which offers protection in the United Kingdom, Germany, France, Spain, Italy, and more.

A 2nd Continuation of the Bravo family of patents is issued by USPTO.

December

The 2nd Divisional Patent of the Charlie family is issued by USPTO.

The 4th Divisional Patent of the Charlie family is issued by USPTO.

Omega receives a Notice of Allowance for the 1st Divisional Patent of the Charlie family.

The 1st Continuation of the Charlie family of patents is issued by USPTO.

The 5th Divisional Patent of the Charlie family is issued by USPTO.

Omega receives a Notice of Allowance for the 3rd Divisional Patent of the Charlie family.

January

The 1st Divisional Patent of the Charlie family is issued by USPTO.

The 3rd Divisional Patent of the Charlie family is issued by USPTO.

March

The Bravo family of patents is filed with the Australian Patent Office.

The 3rd Divisional Patent of the Charlie family is issued by USPTO.

A Notice of Allowance for a 2nd Continuation of Omega's Bravo family of Patents is issued by the USPTO.

May

A 2nd Continuation of the Bravo family of patents is issued by USPTO.

A supplemental provisional application for the Golf family of Patents is filed with the USPTO.

The Bravo family of patents is filed with the Japanese Patent Office.

June

The Delta family of patents is filed with the USPTO.

Omega files a PCT application for the Delta family of patents.

September

The Charlie 6th Divisional patent is granted by the USPTO as U.S. Patent No. 9,763,771.